Thermal ablation acceptable for early lung cancer

Thermal ablation acceptable for early lung cancer

(HealthDay)—Thermal ablation (TA) is a safe, effective treatment for stage 1 non-small cell lung cancer (NSCLC), according to a study recently published in Radiology.

Johannes Uhlig, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues used the 2004 to 2013 National Cancer Database to identify patients with stage 1 NSCLC treated with TA (1,102 patients) or stereotactic radiation therapy (SRT; 27,732 patients).

The researchers found no significant difference in overall survival between TA and SRT during a mean follow-up of 52.4 months (survival difference, P = 0.69) in a propensity score-matched cohort with balanced distribution of potential confounders. During the course of the follow-up period, all survival rates were comparable between TA and SRT (one year, P = 0.76; two years, P = 0.43; three years, P = 0.32; five years, P = 0.81). For patients who underwent TA, unplanned hospital were higher than the readmission rates of those who underwent SRT (3.7 versus 0.2 percent; P < 0.001).

"Regarding overall survival, thermal ablation was non-inferior to for primary treatment of stage 1 non-small-cell ," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further

Thermal ablation effectively treats early-stage lung cancer

More information: Abstract/Full Text
Journal information: Radiology

Copyright © 2018 HealthDay. All rights reserved.

Citation: Thermal ablation acceptable for early lung cancer (2018, October 24) retrieved 28 March 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments